✨ Education and Health Notices
20 FEBRUARY 2014 NEW ZEALAND GAZETTE, No. 19 433
Liberton Christian School, Dunedin (4117).
The said supplementary integration agreement was executed on 11th February 2014.
A copy of the supplementary integration agreement is available for inspection without charge by any member of the public via the following email address:
enquiries.dunedin@minedu.govt.nz
Dated at Wellington this 11th day of February 2014.
LEO TROMPETTER, Acting Group Manager, Sector Enablement and Support, Ministry of Education.
go871
Health
Medicines Act 1981
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Postrelle
Active Ingredient: Levonorgestrel 1.5mg
Dosage Form: Tablet
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Famy Care Limited, Ahmedabad, India
Product: Postrelle-2
Active Ingredient: Levonorgestrel 0.75mg
Dosage Form: Tablet
New Zealand Sponsor: Mylan New Zealand Limited
Manufacturer: Famy Care Limited, Ahmedabad, India
Product: Ramipex
Active Ingredient: Pramipexole hydrochloride monohydrate 0.25mg equivalent to Pramipexole 0.175mg
Dosage Form: Tablet
New Zealand Sponsor: Deva Holdings NZ Limited
Manufacturer: Deva Holding A.S., Tekirdag, Turkey
Product: Ramipex
Active Ingredient: Pramipexole hydrochloride monohydrate 1mg equivalent to Pramipexole 0.7mg
Dosage Form: Tablet
New Zealand Sponsor: Deva Holdings NZ Limited
Manufacturer: Deva Holding A.S., Tekirdag, Turkey
Product: Isentress
Active Ingredient: Raltegravir potassium 434.3mg equivalent to Raltegravir 400mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Merck Sharp & Dohme (New Zealand) Limited
Manufacturers: Merck Sharp & Dohme Corp, Virginia, United States of America
MSD International GmbH (Singapore Branch), Singapore
Dated this 13th day of February 2014.
SUSAN MARTINDALE, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
go973
Corrigendum—Classification of Medicines
In the notice published in the New Zealand Gazette, 7 February 2014, No. 15, page 335, the following entry should read:
under Schedule 1, Prescription Medicines:
"Zoster immunoglobulin, human"
and please insert
"Varicella vaccine; except when administered for the prevention of herpes zoster (shingles) to a person 50 years of age or over by a registered pharmacist who has successfully completed a vaccinator training course approved by the Ministry of Health and who is complying with the immunisation standards of the Ministry of Health"
in alphabetical order.
Dated this 17th day of February 2014.
DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health.
go1070
Next Page →
✨ LLM interpretation of page content
🎓
Supplementary Integration Agreement
(continued from previous page)
🎓 Education, Culture & Science11 February 2014
Private Schools Conditional Integration Act 1975, Supplementary Integration Agreement, Liberton Christian School, Dunedin
- Leo Trompetter, Acting Group Manager, Sector Enablement and Support, Ministry of Education
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social Welfare13 February 2014
Medicines Act 1981, New Medicines, Postrelle, Postrelle-2, Ramipex, Isentress, Levonorgestrel, Pramipexole, Raltegravir
- Susan Martindale, Acting Group Manager, Medsafe, Ministry of Health
🏥 Corrigendum—Classification of Medicines
🏥 Health & Social Welfare17 February 2014
Medicines Classification, Zoster Immunoglobulin, Varicella Vaccine, Pharmacist, Vaccinator Training
- Dr Don Mackie, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health
NZ Gazette 2014, No 19